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OBJECTIVE—The ATP-sensitive K
 channel (KATP) controls
insulin secretion from the islet. Gain- or loss-of-function muta-
tions in channel subunits underlie human neonatal diabetes and
congenital hyperinsulinism (HI), respectively. In this study, we
sought to identify the mechanistic basis of KATP-induced HI in
two probands and to characterize the clinical course.
RESEARCH DESIGN AND METHODS—We analyzed HI in
two probands and characterized the course of clinical treatment
in each, as well as properties of mutant KATP channels expressed
in COSm6 cells using Rb efﬂux and patch-clamp methods.
RESULTS—We identiﬁed mutation V290M in the pore-forming
Kir6.2 subunit in each proband. In vitro expression in COSm6
cells supports the mutation resulting in an inactivating pheno-
type, which leads to signiﬁcantly reduced activity in intact cells
when expressed homomerically, and to a lesser extent when
expressed heteromerically with wild-type subunits. In one het-
erozygous proband, a ﬂuoro-DOPA scan revealed a causal focal
lesion, indicating uniparental disomy with loss of heterozygosity.
In a second family, the proband, homozygous for the mutation,
was diagnosed with severe diazoxide–unresponsive hypersinsu-
linism at 2 weeks of age. The patient continues to be treated
successfully with octreotide and amlodipine. The parents and a
male sibling are heterozygous carriers without overt clinical HI.
Interestingly, both the mother and the sibling exhibit evidence of
abnormally enhanced glucose tolerance.
CONCLUSIONS—V290M results in inactivating KATP channels
that underlie HI. Homozygous individuals may be managed
medically, without pancreatectomy. Heterozygous carriers also
show evidence of enhanced glucose sensitivity, consistent with
incomplete loss of KATP channel activity. Diabetes 60:209–217,
2011
T
he ATP-sensitive K
 channel (KATP) regulates
insulin secretion from the pancreatic -cell by
coupling changes in metabolism to changes in
electrical activity. KATP overactivity suppresses
insulin release and causes neonatal diabetes (1,2),
whereas KATP underactivity causes hypersecretion and
congenital hyperinsulinemia (HI) (3–5).
HI mutations can cause aberrant channel synthesis or
trafﬁcking or altered channel gating (5,6). Mature KATP
channels are hetero-octomers of four pore-forming Kir6.2
subunits (KCNJ11) and four sulfonylurea receptor sub-
units (ABCC8) (7–9). We report a novel Kir6.2 mutation
(V290M), identiﬁed in two unrelated HI probands. V290M
reduces channel activity by causing an inactivating pheno-
type, which explains the HI outcome. Importantly, the
V290M mutation is present in the homozygous state in one
of the HI-affected probands and is heterozygous in the
unaffected parents and one sibling. Oral glucose tolerance
tests (OGTTs) on the heterozygous mother and sibling
suggest hyper-responsivity in both individuals.
RESEARCH DESIGN AND METHODS
Genetics and molecular biology. Genomic DNA was isolated from whole
blood using the DNeasy Tissue Isolation kit (Qiagen, Valencia, CA). KCNJ11
was ampliﬁed by PCR and directly sequenced. The identiﬁed V290M mutation
was engineered into mouse Kir6.2 cDNA in pCMV6B using the Quikchange
site-directed mutagenesis kit (Stratagene, La Jolla, CA) and was conﬁrmed by
direct sequencing.
Clinical studies. Oral glucose tolerance tests (OGTTs): D-glucose was given
orally and blood drawn via peripheral intravenous at baseline and then at
hourly intervals. Samples were assayed for serum glucose, insulin, and
proinsulin at the Mayo Clinical Laboratory (Rochester, MN). For the mother,
the glucose load (Glucola) was 75 g. For the sibling child, the load was 1 g/kg,
and the duration of the OGTT was truncated to 3 h due to age. Of note,
behavioral changes (e.g., hunger, lethargy) that often followed a meal were
reported for the sibling. Given that heterozygous KATP channel mutations have
been identiﬁed in patients with HI (6), the mother requested testing for her
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Continuous glucose monitoring system (CGMS): Due to parental wishes to
decrease the frequency of octreotide injections, medical therapy was adjusted
while monitoring under CGMS as an off-label use. A sensor was placed on
three separate occasions for Proband 1 (CareLink; Medtronic MiniMed) after
application of topical anesthetic. Medtronic (Caremark) provided training to
the parents on how to use devices and mark events such as medication and
meals, as well as to corroborate hypoglycemic (sensor set at 80) or
hyperglycemic (200) events detected by an external blood glucose meter.
Reference ranges were chosen for the alarm settings to avoid hypoglycemia
and minimize glycosuria, as well as to avoid excessive ﬁnger sticks for the
child. Sensors were placed for a maximum of 5 days and corresponded to
periods when treated with 1) octreotide alone or 2) octreotide  amlodipine.
Of note, the child was tapered off amlodipine while on CGMS for a period of
2 weeks. After monitoring with octreotide alone, amlodipine (0.1 mg/kg
divided twice daily) was reintroduced for 5 days prior to CGMS testing.
Baseline glucose levels and excursions (high and low) were documented on a
continuous basis to evaluate the safety and efﬁcacy of the two treatment
regimens.
Fluoro-DOPA analysis of pancreas. Fluoro-DOPA (
18F-L-DOPA) positron
emission tomography/computed tomography study (4 MBq/Kg of
18F-L-DOPA
administered intravenously 45 min before acquisition) was performed using a
hybrid machine (Gemini GXL, Philips Medical Systems). The positron emis-
sion tomography scan was performed under general anesthesia and glucose
infusion to maintain normoglycemia after 6-h fasting and without stopping
medications.
Expression of KATP channels in COSm6 cells. COSm6 cells were cultured
in Dulbecco’s modiﬁed Eagle medium plus 10 mmol/l glucose and supple-
mented with FCS (10%). Cells were transfected with cDNA using FuGENE 6
Transfection Reagent (Roche Diagnostics, Indianapolis, IN) and then plated
on sterile glass coverslips overnight prior to patch-clamp experiments.
Electrophysiological methods. Patch-clamp experiments were performed
at room temperature on COSm6 cells that ﬂuoresced green under ultraviolet
illumination at 3–5 days post-transfection. Membrane patches were voltage-
clamped using an Axopatch 1-D ampliﬁer (Axon Instruments, Union City, CA).
All currents were measured at a membrane potential of 50 mV. Data were
collected using the pClamp8.2 software suite (Axon Instruments, Union City,
CA) and Microsoft Excel. Bath and pipette control solutions (KINT) contained
(mM): 150 KCl, 10 HEPES, and 1 EGTA (pH 7.4). Where indicated, ATP was
added to the bathing solution as dipotassium salts. Tolbutamide was dissolved
in KINT from a 100 mmol/l stock solution in 100 mmol/l KOH.
Macroscopic
86Rb
 efﬂux assays. COSm6 cells in 12-well plates were
incubated for 24 h in culture medium containing
86RbCl (1 Ci/ml) 2 days after
transfection. Cells were washed twice with Ringer’s solution (Basal) (in mM:
118 NaCl, 2.5 CaCl2, 1.2 KH2PO4, 4.7 KCl, 25 NaHCO3, 1.2 MgSO4, 10 HEPES;
pH 7.4) with or without metabolic inhibition (1 mmol/l 2-deoxy-D-glucose and
2.5 g/ml oligomycin). At selected time points, solution was removed and
replaced with fresh solution; after completion of the assay, cells were lysed
with 1% SDS and removed. Collected samples were assayed in a scintillation
solution. Raw data are shown as percent
86Rb
 efﬂux relative to total content.
The rate constant of KATP-speciﬁc
86Rb
 efﬂux (k2) was obtained by ﬁtting
a single exponential equation:
Relative ﬂux  1  exp   k1  k2	 *t 
 (1)
where apparent rate constant for nonspeciﬁc efﬂux (k1) was obtained from
untransfected cells. Glibenclamide was added to Ringer’s solution plus
metabolic inhibition from a 1 mmol/l stock solution in DMSO. Results are
presented as mean  SEM. Statistical tests and P values are noted in the ﬁgure
legends where appropriate.
Estimation of Po,zero using noise analysis. Mean Po,zero was estimated from
stationary ﬂuctuation analysis of macroscopic currents in isolated membrane
patches (10,11). Short (1 s) recordings of currents were analyzed in zero
[ATP] and in 5 mmol/l [ATP] (for estimation of ATP-independent noise).
Currents were ﬁltered at 1 kHz and digitized at 3 kHz with 12-bit resolution.
Mean patch current (I), and variance () in the absence of ATP were obtained
by subtraction of mean current and variance in 5 mmol/l ATP (i.e., assuming
all channels fully closed). Single-channel current (i) was assumed to be 3.75
pA at 50 mV, corresponding to wild-type (WT) single-channel conductance
of 75 pS (12). Po,zero was then estimated from the following equation:
Po,zero  1  
2/i * I	
 (2)
Quantitative analysis of ATP inhibition. The ATP dose–response was
quantiﬁed by ﬁtting the raw data with a Hill equation:
Irel  1/1  
ATP
/k1/2
H	 (3)
where Irel is the current relative to that in the absence of ATP, [ATP] is the
ATP concentration, k1/2 is the half-maximal inhibitory ATP concentration, and
H is the Hill coefﬁcient that was ﬁxed at 1.3.
Immunoblotting. At 48-h post-transfection, cells were washed twice with
cold PBS (137 mmol/l NaCl, 2.7 mmol/l KCl, 10 mmol/l Na2HPO4, 2 mmol/l
KH2PO4) and then incubated at 4°C in 300 l of lysis buffer (150 mmol/l NaCl,
20 mmol/l HEPES, 10 mmol/l EDTA, 1% NP-40, one “Complete Mini” protease
inhibitor [Roche Diagnostics, Indianapolis, IN] per 10 ml at pH 7). Lysates
were centrifuged for 5 min at 13,000 rpm in 4°C and then transferred to clean
microcentrifuge tubes, resolved with SDS-PAGE (7.5% acrylamide), and
transferred to polyvinylidene ﬂuoride membranes presoaked in methanol.
Filters were blocked overnight in TBS-T (Tris-buffered saline with Tween)
buffer (200 mmol/l NaCl, 20 mmol/l Tris-HCl, 0.1% Tween, pH 7.4) plus 5%
nonfat dry milk at 4°C. Filters were incubated and rocked for1hi na1:1,000
dilution of anti-SUR1 antibody (afﬁnity-puriﬁed from rabbit) in TBS-T plus 5%
milk, washed 3 times for 5 min each in TBS-T, then bathed in 1:1,000 dilution
of secondary antibody (goat, anti-rabbit IgG, horseradish peroxidase–linked
[Pierce]) in TBS-T plus 5% milk. Filters were washed an additional 3 times in
TBS-T for 5 min each before appliance of an enhanced chemiluminescence
system for detection of horseradish peroxidase (SuperSignal West Pico
Chemiluminescent Substrate) and subsequent exposure to autoradiography
ﬁlm (Midwest Scientiﬁc, St. Louis, MO).
RESULTS
Genetic pedigree of HI in two separate families with
V290M mutation. Figure 1 shows available pedigrees for
two families in which the neonatal probands were clini-
cally diagnosed with HI. Proband 1 (female, gestation 38
weeks, birth weight [BW] 3.5 kg, 75–90th centile [13]) was
referred by an outside hospital at 2 weeks for evaluation
of persistent hypoglycemia (blood glucose 30 mg/dl),
despite initiation of dextrose-containing intravenous ﬂuids
and diazoxide (15 mg/kg/day). Genotyping (Athena Diagnos-
tics) identiﬁed homozygous V290M mutation in KCNJ11 in
the proband and heterozygous V290M in each of the
unaffected mother (gestation 40 weeks, BW 3.9 kg, 75–90th
centile), father (gestation 40 weeks, BW 4.5 kg, 95–97th
centile), and male sibling (gestation 35 weeks, BW 3.0 kg,
75–90th centile), but not in an unaffected male sibling
(gestation 36 weeks, BW 2.7 kg, 25–50th centile). Addi-
tional sequencing revealed no coding mutations in GCK,
GLUD1,o rABCC8 genes in the proband. The ancestors of
the mother and father came from the same small town in
Germany, suggesting the same founder mutations. There is
a family history of type 2 diabetes in two maternal
great-aunts and a paternal great-grandmother, but no
family history of frank hypoglycemia.
Proband 2 was a female born at 38-weeks’ gestation (BW
3.4 kg, 75–90th centile) to an Italian family and had the ﬁrst
episode of hypoglycemia at day of life (DOL) 2 (blood
glucose 29 mg/dl, treated with glucose infusion). She was
referred at 8 weeks to Bambino Gesu ` Pediatric Hospital
for diffuse cyanosis and tremor; plasma glucose was 40
mg/dl with simultaneously elevated insulin of 215 pmol/l
and low free fatty acids (220 mmol/l). Diazoxide therapy
(15 mg/kg/day) was started and then tapered to 4 mg/kg/
day. Genotyping identiﬁed heterozygous V290M mutation
in KCNJ11 in both the proband and the apparently unaf-
fected father (not available for further testing). Additional
sequencing of proband DNA revealed no coding mutations
in ABCC8, GCK,o rHNF4 genes.
Variable clinical presentation. Shortly after birth, pro-
band 1 developed cyanosis, blood glucose 20 mg/dl, and
was transferred to neonatal intensive care at an outside
hospital. The presence of a heart murmur on DOL 2
prompted an echocardiogram (ECHO) that detected a
small patent ductus arteriosus, which resolved spontane-
ously. Despite frequent breast-feeding, supplemental, and
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continued. Diazoxide treatment was initiated at 15 mg/kg/
day on DOL 10. Laboratory assessment prior to initiation
of diazoxide revealed insulin levels of 56 and 70 pmol/l on
two occasions when blood glucose was 40 mg/dl. Pitu-
itary testing at the time of hypoglycemia showed intact
counterregulatory responses (not shown). In family 2,
both the proband and the father carry the V290M mutation
in KCNJ11, yet only the proband suffers from HI. Lack of
mutations in other candidate genes suggested paternal
uniparental disomy with loss of heterozygosity of the
maternal allele, characteristic of focal HI (14). Fluoro-
DOPA scanning (Fig. 1B) provided clear evidence of a
focal lesion in the body of the pancreas. Extemporary
histological examination performed during surgery re-
vealed focal adenomatous hyperplasia of islet cells,
prompting complete excision of the lesion and effectively
curing the patient and providing further corroborative
evidence of focal HI.
Clinical course and treatment experience in proband
1. At DOL 16, proband 1 was transferred to the University
of North Carolina Children’s Hospital. Blood glucose was
40 mg/dl, and the patient was still receiving diazoxide. In
addition, the repeat insulin level was 42 pmol/l with blood
glucose of 38 mg/dl. She was started on subcutaneous
octreotide (4 g/kg/day given in divided doses every 8 h).
Due to persistent hypoglycemia and concomitant tachyph-
lyaxis, which is commonly found with octreotide (15),
dosing was increased steadily to 12 g/kg/day (divided
doses every 6 h). Diazoxide was tapered off and fasting
blood glucose was maintained at 60 mg/dl. On DOL 21,
ECHO revealed systolic murmur, mild/moderate left ven-
tricular hypertrophy (LVH), and mild hypertension for age
(blood pressure 80–90 mmHg [systolic]/30–40 mmHg [di-
astolic]). Consequently, amlodipine (0.1 mg/kg/day given
in divided dosing twice daily orally) was initiated to treat
both LVH and associated hypertension. The repeat ECHO
at DOL 46 was normal.
CGMS evaluation. Proband 1 is currently 6-years-old
with normal A1C (5.6%), impaired fasting glucose-1 (123
ng/ml), Insulin-like growth factor BP3 (4.3 g/ml), and
serum insulin (119 pmol/l) at ambient glucose of 78 mg/dl.
Growth is steady between the 25–50 percentile on oct-
reotide (now 8 g/kg/day divided 4 times daily). Histori-
cally, she was allowed to outgrow her amlodipine. Due to
the desire to decrease the frequency of injections, reintro-
duction of amlodipine was evaluated systematically using
CGMS (CareLink, Medtronic) (RESEARCH DESIGN AND
METHODS).
Given the long-standing debate as to the usefulness of
calcium channel antagonists in HI treatment (16,17),
CGMS also permitted ascertaining the response to amlo-
FIG. 1. V290M pedigrees and clinical responses to therapy. A: Arrow indicates the V290M proband in each case; black, gray, and empty symbols
indicate genetically homozygous, heterozygous, and unaffected individuals, respectively. B: Results of ﬂuoro-DOPA scan of proband 2 indicates
focal lesion (yellow arrowheads) in the body of the pancreas. C: Mean daily glucose levels and SD for ﬁnal period on octreotide alone (8 g/kg/day
divided every 6 h), following switch to octreotide 8 g/kg/day divided every 6 h plus amlodipine (0.1 mg/kg/day divided every 12 h). Gray area
represents target range for alarm for CGMS (70–140 mg/dl glucose). mo, month. (A high-quality digital representation of this ﬁgure is available
in the online issue.)
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inhibition of -cell calcium channels (18) and/or via inhi-
bition of these channels through decreases in cyclic AMP
(19). The additive effects of amlodipine plus octreotide
therefore would be expected to help to minimize the
peak/trough effects of each individual agent. As shown in
Fig. 1C, octreotide alone maintained average blood glu-
cose levels in the desired range, but marked excursions
were still present with episodes 300 mg/dl. There was
only one episode of blood glucose 60 mg/dl in 3,000
sensor readings (Fig. 1B). Following the introduction of
amlodipine, baseline mean blood glucose rose and stabi-
lized at a higher level than with octreotide alone, and there
were no episodes of blood glucose levels 60 mg/dl in the
presence of octreotide plus amlodipine. Subsequent intro-
duction of bedtime cornstarch further improved control
without dangerous excursions but was not tolerated due
to typical side effects of bloating and abdominal discom-
fort, and it was discontinued.
Effect of V290M mutation on KATP channels ex-
pressed in COSm6 cells. To examine the mutation
effects on KATP channel activity, we measured
86Rb
 efﬂux
across the plasma membrane of COSm6 cells cotrans-
fected with SUR1, and WT Kir6.2, Kir6.2[V290M], or 1:1
mixture of these subunits. Efﬂux curves were ﬁt with the
two-pathway model (RESEARCH DESIGN AND METHODS), un-
transfected cells providing the efﬂux rate (k1) for the
non-KATP pathway. Homomeric Kir6.2[V290M] (M/M)
channels show considerably reduced
86Rb efﬂux rates,
with k2 reduced by 80% under metabolically inhibited or
diazoxide-stimulated conditions (Fig. 2). Cells expressing
heteromeric WT plus V290M (V/M) channels show inter-
mediate efﬂux rates (k2, reduced by 50%) (Fig. 2B).
These data conﬁrm that the V290M mutation results in
reduced KATP channel activity in intact cells and predict
that insulin hypersecretion will be seen in vivo for het-
erozygous carriers and more severely so in the homozy-
gous state.
Inactivating phenotype of V290M channels. Lysates of
COSm6 cells expressing recombinant channels were as-
sayed by immunoblotting (Fig. 3A). Anti-SUR1 blots show
a doublet at 170 kDa, corresponding to SUR1 protein,
with a similar fraction of complex-glycosylated SUR1 to
WT, indicating that the lower activity observed in V290M
channels is not due to reduced channel density at the
surface of the plasma membrane.
The activity of WT and mutant KATP channels was
further examined in inside-out membrane patch-clamp
experiments (Figs. 3–5). Upon membrane excision, WT
channels typically open to a steady-state level with open
probability of 0.3–0.5 (20). In marked contrast, V290M
channels open but then exhibit a rapid decay in macro-
scopic current, typically resulting in much smaller steady-
state currents than is observed in WT channels. Following
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constant of 2.0  0.5 s (n  5), while WT channels showed
essentially no inactivation following excision (Fig. 3B).
Steady-state ATP sensitivity of V290M channels was simi-
lar to WT (Fig. 4A and C), but current density was
considerably lower than WT (Fig. 4B), reﬂecting the
dramatic inactivation that occurs. Physiologically, the
major determinant of channel activation is stimulation by
Mg-nucleotides and, as shown in Fig. 4D, MgADP activa-
tion is intact in V290M channels, although inactivation
follows the MgADP activation, reducing steady-state cur-
rents in MgADP.
PIP2 rescues channels from the inactivated state.
Following patch excision, exogenously applied phosphati-
dylinositol bisphosphate (PIP2) incorporates into the
membrane inner leaﬂet and typically increases activity of
WT channels by two- to threefold as a result of increased
open-state stability (21,22) (Fig. 5). Following inactivation
to steady-state levels, application of PIP2 to V290M
patches caused much greater relative increase in current
(50-fold) to 1902.58  560.63 pA (n  8), similar to the
WT patch current on excision. During PIP2 exposure,
inactivation became progressively slower and less com-
plete in response to application and removal of ATP (Fig.
5B). During this process, the rate and extent of inactiva-
tion both decreased in correlation with the estimated open
probability (Fig. 6A) as expected for an inactivation pro-
cess occurring from the closed state (DISCUSSION).
OGTT evaluation in heterozygous carriers in family
1. In mouse models of reduced KATP, even 50% reduction
is sufﬁcient to cause enhanced glucose tolerance and
hypersecretion of insulin (23,24). Given that hetero-
meric V290M/WT channels exhibit 50% reduction of
KATP conductance (Fig. 2) and the anecdotal evidence of
hypersensitivity to glucose exhibited by the proband’s
brother, we pursued OGTT in the mother (Table 1) and
the brother (Table 2), both of whom are heterozygous
for the V290M mutation. Blood glucose in healthy adults
will be below 200 mg/dl at 1 h and below 140 mg/dl at
2 h; in healthy children, it will be 100 mg/dl at 1 h (25).
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FIG. 3. Molecular basis of loss of KATP activity. A: Western blots of FLAG-tagged SUR1 (fSUR1) from COSm6 cells expressing fSUR1 alone, or
co-expressing fSUR1 with either WT Kir6.2 or mutant Kir6.2[V290M]. The mature (cell surface) complex-glycosylated and immature core-
glycosylated fSUR1 bands are indicated by upper and lower arrows, respectively. In the absence of Kir6.2, fSUR1 is exclusively core glycosylated.
B: Representative currents recorded by inside-out excised patch-clamp technique from COSm6 cells expressing WT or mutant V290M KATP
channels at 50 mV membrane potential (50 mV pipette). Patches were excised from the cell (arrow) into zero ATP solution, then subsequently
exposed to 5 mmol/l ATP. C: Structural model of Kir6.2 tetramer (46) indicates location of V290. R301 and E292 of adjacent Kir6.2 subunits form
a salt bridge that is essential for channel function. V290 lies within seven angstroms of R301, and mutations at this site may destabilize the
intersubunit interface. (A high-quality digital representation of this ﬁgure is available in the online issue.)
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HI under-fed conditions, glucose was close to fasting
levels in both at 1 h, and even lower at 2 h, suggestive of
a “supranormal” response. Proinsulin levels rose during
OGTT and, although within the reported ranges for
healthy subjects (26), proinsulin-to-insulin ratios at 1
a n d2hw e r eabove the normal range for young individ-
uals (26).
DISCUSSION
Molecular basis of HI associated with Kir6.2[V290M]
mutation. We describe two unrelated families with the
Kir6.2[V290M] mutation. By recombinant expression of
WT or V290M mutant Kir6.2 subunits, we show that the
mutation results in partial loss of KATP channel activity in
the heterozygous case and more severe loss in the ho-
mozygous case (Fig. 2). The loss of function results from
induction of an inactivation phenomenon (Fig. 3B), which
is similar to that resulting from HI-associated mutations at
Kir6.2 residue R301 (27). These mutations resulted in both
loss of functional membrane channels and an inactivating
phenotype. The V290M mutation seems to reduce channel
activity solely through induction of inactivation since
surface expression appears normal (Fig. 3A). Structural
analysis suggests that V290 participates in the generation
of an inter-subunit salt bridge involving R301 and E290
(Fig. 3C). We suggest that V290M and R301 mutations
induce the same inactivating phenotype by destabilizing
this salt bridge, causing the channel to enter a long-lived
inactivated state after closure in the absence of ATP. The
observed relationship between K1/2,ATP and open probabil-
ity is an emergent property of gating schemes in which
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nel (28), and loss of inactivation paralleling increase in
open-state stability with PIP2 is then predicted by the
assumption that inactivation occurs from the unliganded
closed state (Fig. 6B).
Variable presentation of HI associated with
Kir6.2[V290M] mutation. In family 1, HI in the neonatal
period is clearly associated with the homozygous condi-
tion. In the proband of family 2, the mutation presents in a
focal lesion with loss of heterozygosity. KATP channel
activity reduction is graded from the heteromeric to the
homomeric expression with severe (80%) loss in the
homomeric case; this is consistent with the clinical HI
phenotype of these two probands. In the heterozygous
case, reduction of channel activity is 50%. Previous
extensive studies of animal models of genetic suppression
of KATP activity predict that such a reduction is sufﬁcient
to cause glucose hyperresponsivity with left-shifted glu-
cose-dependence of insulin secretion, but unaltered basal
secretion (29–31). The relevance of this to humans re-
mains unclear, but seems a reasonable explanation for the
apparent glucose hyperresponsivity of the two carrier
relatives in family 2. In this regard, it is notable that the
affected probands in each family and the three unaffected
heterozygous carriers in family 1 were at the upper range
of normal birthweights and large relative to the unaffected
sibling. The anecdotal observation of the mother in family
1 that the 4-year-old heterozygous-carrier child can be-
come hungry and/or lethargic after eating might reﬂect
postprandial hypoglycemia and may warrant caution dur-
ing meals and/or modiﬁcation of meal carbohydrate com-
position for such an individual. There are few published
studies focusing on heterozygous carriers of HI mutations.
Huopio et al. (32) reported that carriers of the SUR1 V187D
mutation had normal glucose tolerance and insulin secre-
tory capacity. However, V187D reduces KATP channel
activity by affecting trafﬁcking to the surface membrane,
and this is readily reversible, even simply by exposure to
sulfonylureas (33). It is unclear whether the presence of
even a single WT subunit might be sufﬁcient for normal
trafﬁcking in the heterozygous case, such that there is
minimal effect on KATP density in heterozygous carriers.
Otherwise, for recessive loss of function HI mutations that
do cause reduction in channel density in the heterozygous
case, it seems that glucose hyperresponsivity might be a
feature, although clearly this requires further study in
bigger cohorts.
There are now several reports of patients with HI due to
loss-of-function KATP mutations “crossing-over” to diabe-
tes in later life, including heterozygous carriers of SUR1
mutations (34,35). Again, this is predicted from mouse
models of the loss of KATP activity (36,31), which become
glucose-intolerant as adults and diabetic on high-fat diets.
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FIG. 6. Kinetic mechanism of inactivation. A: Fraction of inactivating
current (following ATP removal) vs. steady-state current (relative to
maximal attained following repeat PIP2 exposure–relative open prob-
ability) at selected time points following exposures to PIP2 in V290M
channels. Individual patches are indicated by different symbols; large
symbols indicate starting values prior to ﬁrst exposure to PIP2. B:A
3-state model of channel activity (with an unliganded open and closed
state, and with ATP binding to the closed state) is adequate to explain
multiple features of KATP gating (28,47,48). A fourth, inactivated, state
(CIN), which is coupled to the unliganded closed state, can explain both
the phenomenon of inactivation and the ﬁnding that PIP2 (which acts
to shift the KCO equilibrium toward the open state) both reduces and
slows inactivation.
TABLE 1
OGTT in heterozygous mother
Time
Serum glucose
(mg/dl)
Insulin
(pmol/l)
Proinsulin
(pmol/l)
Proinsulin-to-
insulin ratio
Baseline 82 40.6 3.4 0.083:744
1 h 75 350 17 0.048:571
2 h 74 133 13 0.097:744
3 h 63 14 6.7 0.478:571
4 h 72 9.1 4.7 0.516:484
5 h 73 6.3 3.1 0.492:063
1 min
V290M
WT
1 nA
PIP2
ATP
500pA
5s
PIP2
ATP A
B
FIG. 5. Inactivation is PIP2-sensitive. Current recordings of COSm6
patches expressing WT (A) and mutant V290M (B) channels. In WT
channels, the current approximately doubles following addition of
PIP2. However, in V290M channels, steady-state channel activity in-
creases several-fold, accompanied by a marked reduction in inactiva-
tion following exposures to PIP2, a channel open-state stabilizer.
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heterozygous carriers were in the normal range (0.1–0.2)
in the fasted state and fell appropriately in the ﬁrst hour of
the OGTT, but then rose to relatively higher levels at 2 and
3 h than has been reported for healthy young subjects, and
reminiscent of the elevated ratios seen in type 2 diabetics
(26,37). Conceivably, this apparently elevated proinsulin-
to-insulin ratio reﬂects so-called -cell overwork and
might be a harbinger of a tendency to crossover later in
life.
Treatment options for KATP-dependent HI. Standard
treatment options for HI are essentially limited to diazox-
ide (activating KATP and suppressing insulin secretion) or
octreotide (long-acting somatostatin analog suppressing
glucose actions on the -cell), glucagon (counterregulator
to insulin) or subtotal pancreatectomy (17,38–40). L-type
(dihydropyridine-sensitive, CaV1) channel blockers are
mechanistically an attractive option to directly modulate
insulin secretion. Previous results have been mixed
(16,41), but some patients have achieved stable blood
glucose levels on nifedipine monotherapy. In the present
case, improvement in both LVH and hypertension in
addition to hypoglycemia are shown in a neonate on both
amlodipine and octreotide. The contribution of amlodipine
to blood glucose was assessed more directly using CGMS
when the proband became of school-age. The main ﬁnding
was a rise in basal glucose levels with no values below 70
mg/dl while on the same dose of octreotide in the presence
of amlodipine. Given its mechanism of Cav1 channel
inhibition, this ﬁnding is not surprising and supports the
results of Aynsley-Green and colleagues (42). In the
present case, amlodipine also permitted extension of
octreotide dosing from every6ht oevery 8 h, thereby
saving 1 injection daily (a signiﬁcant improvement in
quality of life).
A key clinical management question for HI is whether to
pursue medical or surgical therapy. Long-term medical
therapy, as in this case, presents a less expensive option
than subtotal pancreatectomy, which is the procedure that
would be indicated by the mutation and mode of inheri-
tance. In addition, excellent glucose control, normal
growth and development, and the variable risk of postsur-
gical diabetes all support this management to date for this
child. Moreover, glucose levels normalize and medical
therapy can be stopped at some point for many HI children
(41,43–45), whereas patients who undergo major resection
of the pancreas will tend to develop diabetes at or around
puberty, another consideration when assessing the pros
and cons of surgical versus medical management.
We report on HI due to a KATP mutation that results in an
inactivating channel in two different families. A homozy-
gous-affected child is well controlled with medical therapy
without surgery. Clinically unaffected heterozygous carri-
ers show signs of hypersecretion, and we suggest that they
may represent an unappreciated cohort with subclinical
features.
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